Stay informed, stay ahead.
Novo Nordisk is actively working to preserve Medicaid coverage for its obesity drug, Wegovy, as several U.S. states plan to reduce or eliminate reimbursement due to rising costs. The company previously lobbied 14 states to include Wegovy in Medicaid, arguing that the drug could lower long-term healthcare expenses by reducing obesity-related conditions. However, states like…
Shares of Danish drug maker Novo Nordisk sank about 5-6 % on Friday after U.S. President Donald Trump promised major price cuts for popular weight-loss treatments. The drop reflects investor fears that revenue from drugs like Ozempic and Wegovy might shrink. Trump, speaking at a White House event on drug costs and fertility treatments, singled…
Danes’ biotech powerhouse Novo Nordisk has agreed to pay up to $2.1 billion to license and acquire rights to Omeros’ experimental drug, zaltenibart, positioning itself for a bigger role in rare disease treatment. Under the deal, Novo will gain global development and marketing rights to zaltenibart, while Omeros receives $340 million upfront, plus additional milestone…
Novo Nordisk has quietly initiated job cuts at its Clayton, North Carolina facility—the company’s largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs—according to LinkedIn profiles and internal posts. These reductions target frontline roles from quality control to production technicians, underscoring how deep the restructuring is going under new CEO Mike Doustdar. The…
